Fisher Asset Management’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.01M | Hold |
33,996
| – | – | ﹤0.01% | 688 |
|
|
2025
Q4 | $1.3M | Sell |
33,996
-5,345
| -14% | -$174K | ﹤0.01% | 639 |
|
|
2025
Q3 | $940K | Sell |
39,341
-3,841
| -9% | -$72.2K | ﹤0.01% | 698 |
|
|
2025
Q2 | $639K | Hold |
43,182
| – | – | ﹤0.01% | 751 |
|
|
2025
Q1 | $774K | Hold |
43,182
| – | – | ﹤0.01% | 725 |
|
|
2024
Q4 | $752K | Hold |
43,182
| – | – | ﹤0.01% | 706 |
|
|
2024
Q3 | $604K | Hold |
43,182
| – | – | ﹤0.01% | 731 |
|
|
2024
Q2 | $355K | Hold |
43,182
| – | – | ﹤0.01% | 847 |
|
|
2024
Q1 | $333K | Hold |
43,182
| – | – | ﹤0.01% | 848 |
|
|
2023
Q4 | $388K | Hold |
43,182
| – | – | ﹤0.01% | 816 |
|
|
2023
Q3 | $386K | Hold |
43,182
| – | – | ﹤0.01% | 884 |
|
|
2023
Q2 | $663K | Hold |
43,182
| – | – | ﹤0.01% | 838 |
|
|
2023
Q1 | $971K | Sell |
43,182
-15,691
| -27% | -$334K | ﹤0.01% | 778 |
|
|
2022
Q4 | $1.24M | Sell |
58,873
-7,489
| -11% | -$159K | ﹤0.01% | 733 |
|
|
2022
Q3 | $1.64M | Hold |
66,362
| – | – | ﹤0.01% | 605 |
|
|
2022
Q2 | $1.61M | Sell |
66,362
-83
| -0.1% | -$2.09K | ﹤0.01% | 562 |
|
|
2022
Q1 | $1.71M | Buy |
66,445
+22,327
| +51% | +$593K | ﹤0.01% | 572 |
|
|
2021
Q4 | $1.37M | Buy |
44,118
+15,938
| +57% | +$449K | ﹤0.01% | 603 |
|
|
2021
Q3 | $683K | Buy |
28,180
+6,110
| +28% | +$112K | ﹤0.01% | 679 |
|
|
2021
Q2 | $322K | Hold |
22,070
| – | – | ﹤0.01% | 792 |
|
|
2021
Q1 | $551K | Hold |
22,070
| – | – | ﹤0.01% | 694 |
|
|
2020
Q4 | $602K | Sell |
22,070
-4,247
| -16% | -$99.2K | ﹤0.01% | 672 |
|
|
2020
Q3 | $486K | Sell |
26,317
-14,439
| -35% | -$281K | ﹤0.01% | 664 |
|
|
2020
Q2 | $832K | Sell |
40,756
-5,734
| -12% | -$91.3K | ﹤0.01% | 592 |
|
|
2020
Q1 | $678K | Sell |
46,490
-13,700
| -23% | -$206K | ﹤0.01% | 585 |
|
|
2019
Q4 | $855K | Hold |
60,190
| – | – | ﹤0.01% | 602 |
|
|
2019
Q3 | $698K | Hold |
60,190
| – | – | ﹤0.01% | 645 |
|
|
2019
Q2 | $1.21M | Buy |
60,190
+10,260
| +21% | +$203K | ﹤0.01% | 588 |
|
|
2019
Q1 | $1.13M | Sell |
49,930
-30
| -0.1% | -$663 | ﹤0.01% | 577 |
|
|
2018
Q4 | $1.13M | Buy |
49,960
+30
| +0.1% | +$746 | ﹤0.01% | 585 |
|
|
2018
Q3 | $1.43M | Sell |
49,930
-16,402
| -25% | -$469K | ﹤0.01% | 554 |
|
|
2018
Q2 | $1.81M | Sell |
66,332
-21,573
| -25% | -$574K | ﹤0.01% | 538 |
|
|
2018
Q1 | $1.97M | Hold |
87,905
| – | – | ﹤0.01% | 520 |
|
|
2017
Q4 | $1.85M | Buy |
87,905
+12,260
| +16% | +$280K | ﹤0.01% | 525 |
|
|
2017
Q3 | $1.88M | Buy |
+75,645
| New | +$1.67M | ﹤0.01% | 510 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
Fisher Asset Management's TVTX Position: Q1 2026 in Review
Fisher Asset Management held its Travere Therapeutics (TVTX) position steady in Q1 2026 at 33,996 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #688.
Fisher Asset Management first reported a position in TVTX in Q3 2017 and has held it in 35 quarters since. The position peaked at $1.97M in Q1 2018. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- Fisher Asset Management held 33,996 shares of Travere Therapeutics worth $1.01M as of Q1 2026.
- Fisher Asset Management left its Travere Therapeutics share count unchanged in Q1 2026.
- Travere Therapeutics made up ﹤0.01% of Fisher Asset Management's portfolio in Q1 2026, its #688 holding.
- Fisher Asset Management first reported a position in Travere Therapeutics in Q3 2017 and has held it in 35 quarters since.
- Fisher Asset Management's Travere Therapeutics position peaked at $1.97M in Q1 2018.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.